search
Back to results

The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension (SDHDS)

Primary Purpose

Arterial Hypertension, Hypertension, Resistant to Conventional Therapy, Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
spironolactone
placebo
Sponsored by
Ib Abildgaard Jacobsen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Arterial Hypertension focused on measuring hypertension, spironolactone, antihypertensive treatment, Type-2 diabetes

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age < 75 years
  • Type-2 diabetes
  • Therapy resistant hypertension (by ABPM)
  • Treatment with at least 3 antihypertensives

Exclusion Criteria:

  • HbA1c > 10.0
  • BP > 180/110 mmHg
  • Secondary hypertension
  • Intolerance to spironolactone
  • Permanent treatment with nonsteroidal antiinflammatory drugs or systemic glucocorticoids
  • Total cholesterol 10 mmol/l
  • New York Heart Association class III and IV
  • Pregnancy or planned pregnancy
  • Psychiatric disease
  • Malignant disease
  • Insufficient adherence

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    addition of spironolactone

    Placebo

    Arm Description

    spironolactone is added to previous antihypertensive treatment

    Addition of placebo

    Outcomes

    Primary Outcome Measures

    Change of of Systolic Blood Pressure
    Change of systolic blood pressure from baseline to study end at four months.
    Change of Diastolic Blood Pressure
    Change of diastolic blood pressure from baseline to study end at four months.

    Secondary Outcome Measures

    Adverse Effects

    Full Information

    First Posted
    February 3, 2010
    Last Updated
    April 8, 2014
    Sponsor
    Ib Abildgaard Jacobsen
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01062763
    Brief Title
    The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
    Acronym
    SDHDS
    Official Title
    South Danish Hypertension and Diabetes Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    March 2010 (undefined)
    Primary Completion Date
    March 2012 (Actual)
    Study Completion Date
    May 2012 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Ib Abildgaard Jacobsen

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to estimate the effect of spironolactone on blood pressure resistant to therapy in type-2 diabetics.
    Detailed Description
    The primary object of the study is to estimate the effect of addition of low dose spironolactone to antihypertensive treatment with at least three antihypertensive drugs in patients with type-2 diabetes and blood pressure over 130/80 mmHg. Secondary aims are to estimate how many of these patients have their blood pressure controlled by the addition of spironolactone, to investigate whether the addition of spironolactone affects insulin sensitivity and urinary protein secretion and to estimate the incidence of adverse effects of the aldosterone antagonist.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Arterial Hypertension, Hypertension, Resistant to Conventional Therapy, Diabetes Mellitus
    Keywords
    hypertension, spironolactone, antihypertensive treatment, Type-2 diabetes

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    119 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    addition of spironolactone
    Arm Type
    Experimental
    Arm Description
    spironolactone is added to previous antihypertensive treatment
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Addition of placebo
    Intervention Type
    Drug
    Intervention Name(s)
    spironolactone
    Intervention Description
    25 to 50 mg once daily
    Intervention Type
    Drug
    Intervention Name(s)
    placebo
    Intervention Description
    addition of placebo 1 to 2 tablets daily
    Primary Outcome Measure Information:
    Title
    Change of of Systolic Blood Pressure
    Description
    Change of systolic blood pressure from baseline to study end at four months.
    Time Frame
    4 months
    Title
    Change of Diastolic Blood Pressure
    Description
    Change of diastolic blood pressure from baseline to study end at four months.
    Time Frame
    4 months
    Secondary Outcome Measure Information:
    Title
    Adverse Effects
    Time Frame
    4 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age < 75 years Type-2 diabetes Therapy resistant hypertension (by ABPM) Treatment with at least 3 antihypertensives Exclusion Criteria: HbA1c > 10.0 BP > 180/110 mmHg Secondary hypertension Intolerance to spironolactone Permanent treatment with nonsteroidal antiinflammatory drugs or systemic glucocorticoids Total cholesterol 10 mmol/l New York Heart Association class III and IV Pregnancy or planned pregnancy Psychiatric disease Malignant disease Insufficient adherence
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ib A Jacobsen, DMSc
    Organizational Affiliation
    Odense University Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    11821720
    Citation
    Elliott HL, Elawad M, Wilkinson R, Singh SP. Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system. J Hypertens. 2002 Feb;20(2):333-8. doi: 10.1097/00004872-200202000-00025.
    Results Reference
    background
    PubMed Identifier
    14573330
    Citation
    Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov;16(11 Pt 1):925-30. doi: 10.1016/s0895-7061(03)01032-x.
    Results Reference
    background
    PubMed Identifier
    16814132
    Citation
    Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens. 2006 Jul;19(7):750-5. doi: 10.1016/j.amjhyper.2005.11.016.
    Results Reference
    background
    PubMed Identifier
    17309946
    Citation
    Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007 Apr;49(4):839-45. doi: 10.1161/01.HYP.0000259805.18468.8c. Epub 2007 Feb 19.
    Results Reference
    background
    PubMed Identifier
    33107592
    Citation
    Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.
    Results Reference
    derived
    PubMed Identifier
    24739800
    Citation
    Oxlund CS, Cangemi C, Henriksen JE, Jacobsen IA, Gram J, Schousboe K, Tarnow L, Argraves WS, Rasmussen LM. Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension. J Hum Hypertens. 2015 Jan;29(1):28-32. doi: 10.1038/jhh.2014.27. Epub 2014 Apr 17.
    Results Reference
    derived

    Learn more about this trial

    The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension

    We'll reach out to this number within 24 hrs